Evidence map›Paper›PMID 37833390›Full record

ArticleScientific reports2023

Neutralization against Omicron sublineages (BA.2/BA.5/BQ.1.1/XBB/XBB.1.5) in bivalent BNT162b2-vaccinated HCWs with or without risk factors, or following BT infection with Omicron.

Masayuki Amano, Sachiko Otsu, Yukari Uemura, Yasuko Ichikawa, Shota Matsumoto, Nobuyo Higashi-Kuwata, Shuzo Matsushita, Shinya Shimada, Hiroaki Mitsuya

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 12 citations in OpenAlex.

  1. Observational
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Masayuki AmanoDepartment of Clinical Retrovirology, Joint Research Center for Human Retrovirus Infection, Kumamoto University, 2-2-1 Honjo, Cyuou-ku, Kumamoto, 860-0811, Japan. mamano@kumamoto-u.ac.jp.
Sachiko OtsuDepartment of Clinical Retrovirology, Joint Research Center for Human Retrovirus Infection, Kumamoto University, 2-2-1 Honjo, Cyuou-ku, Kumamoto, 860-0811, Japan.
Yukari UemuraDepartment of Data Sciences, Center for Clinical Sciences, National Center for Global Health and Medicine (NCGM), Tokyo, Japan.
Yasuko IchikawaKumamoto General Hospital, Japan Community Healthcare Organization (JCHO), Kumamoto, Japan.
Shota MatsumotoKumamoto General Hospital, Japan Community Healthcare Organization (JCHO), Kumamoto, Japan.
Nobuyo Higashi-KuwataDepartment of Refractory Viral Diseases, NCGM Research Institute, Tokyo, Japan.
Shuzo MatsushitaDepartment of Clinical Retrovirology, Joint Research Center for Human Retrovirus Infection, Kumamoto University, 2-2-1 Honjo, Cyuou-ku, Kumamoto, 860-0811, Japan.
Shinya ShimadaKumamoto General Hospital, Japan Community Healthcare Organization (JCHO), Kumamoto, Japan.
Hiroaki MitsuyaDepartment of Refractory Viral Diseases, NCGM Research Institute, Tokyo, Japan.
Japan Community Healthcare Organization · JPKumamoto University · JPNational Center for Global Health and Medicine · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

SARS-CoV-2-BA.4/5-adapted-bivalent-BNT162b2-vaccine (

Indexed as

BNT162 VaccineBreakthrough InfectionsAntibodies, NeutralizingAntibodies, ViralCohort StudiesHumansImmune EvasionRisk FactorsVaccines, CombinedAntibodies, NeutralizingAntibodies, ViralBNT162 VaccineVaccines, Combined

Identifiers

PMID37833390
PMCPMC10575932
OpenAlexW4387617353

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.